

Supplementary data

Table S1. Compounds, their suppliers, and catalogue numbers.

Name	Cat #	Company
Recombinant human IFN α 1b	11343594	ImmunoTools
Recombinant human IFN α 2a	11343504	ImmunoTools
Recombinant human IFN α 2b	11343514	ImmunoTools
Recombinant human IFN β 1a	11343520	ImmunoTools
Recombinant human IFN β 1b	11343542	ImmunoTools
Recombinant human IFN γ	11343534	ImmunoTools
Recombinant human IFN ω 1	11344784	ImmunoTools
Recombinant human IL28A	11340280	ImmunoTools
Recombinant human IL-29	11340290	ImmunoTools
Camostat mesylate	16018	Cayman Chemicals
Remdesivir	30354	Cayman Chemicals
Lamivudine	S1706	Selleckchem
Cycloheximide	C7698-1g	SigmaAldrich
Pimodivir	HY-12353A/CS	MedChemExpress
EIDD-2801	HY-135853	MedChemExpress




Fig. S1. Examples of IFN-based combinations and their developmental statuses. Data was retrieved from the <https://antiviralcombi.info> database.






Fig. S2. Metabolomic analysis of mock- and SARS-CoV-2-infected Calu-3 cells non-treated or treated with type I IFNs.



b

		IFNa2a	Conv. Serum	Camostat	EIDD-2801	Remdesivir	Cycloheximide
DSS	Fluorescence	34.4	26.7	25.8	16.3	33.6	39.4
	CTG	19.4	33.0	35.6	18.0	29.5	31.3

Fig. S3. Effect of 6 drugs on SARS-CoV-2-mCherry-mediated expression of mCherry and virus-mediated death of Calu-3 cells.



b

Drug combination	Synergy score	Most synergistic area score
Remdesivir (uM) - IFNa2a, ng/ml	6.378	11.69
Cycloheximide (uM) - IFNa2a, ng/ml	5.949	12.19
EIDD-2801 (uM) - IFNa2a, ng/ml	7.94	9.16
Conv. serum (dilution factor) - IFNa2a, ng/ml	21	29.91

Fig. S4. Effect of remdesivir, EIDD-2801, cycloheximide, and convalescent serum in combination with IFNa2a on mCherry-expressing SARS-CoV-2 infection in Calu-3 cells.